Please assess the completion status of the following clinical trial:

Trial Title: Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Undergoing allogeneic hematopoietic stem cell transplantation\* from a major histocompatability complex (MHC)-identical related donor for 1 of the following:~  * Primary refractory acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL)~ * AML or ALL beyond first remission~ * Therapy-related AML at any stage~ * Philadelphia chromosome (bcr-abl)-positive p190-positive ALL at any stage~ * Acute leukemia at any stage arising from myelodysplastic syndromes or myeloproliferative disorders, including any of the following:~    * Chronic myelomonocytic leukemia~   * Chronic myelogenous leukemia~   * Polycythemia vera~   * Essential thrombocytosis~   * Agnogenic myeloid metaplasia with myelofibrosis~ * Refractory anemia with excess blasts~ * Refractory anemia with excess blasts in transformation NOTE: \*Patients must be enrolled on study prior to undergoing transplantation~* Relapsed disease post-transplantation, as evidenced by 1 of the following criteria:~  * Morphologic relapse, as defined by 1 or more of the following:~    * Peripheral blasts in the absence of growth factor therapy~   * Bone marrow blasts \> 5% of nucleated cells~   * Extramedullary chloroma or granulocytic sarcoma~ * Flow cytometric relapse, as defined by the appearance of cells with abnormal immunophenotype consistent with leukemia relapse in the peripheral blood or bone marrow (detected before transplantation)~ * Cytogenetic relapse, as defined by the appearance in 1 or more metaphases from bone marrow or peripheral blood cells of either a non-constitutional cytogenetic abnormality detected in at least 1 cytogenetic study performed before transplantation OR a new abnormality known to be associated with leukemia~ * Molecular relapse, as defined by 1 of the following:~    * 1 or more positive polymerase chain reaction (PCR) assays for clonotypic immunoglobulin heavy chain or T-cell receptor gene rearrangement in patients transplanted for B- or T-cell ALL respectively~   * 1 or more positive post-transplantation reverse transcription PCR assays for p190 BCR-ABL mRNA fusion transcripts in patients transplanted for Philadelphia chromosome-positive p190-positive ALL~* No grade III or IV acute graft-versus-host disease (GVHD)\*\*~* No extensive chronic GVHD\*\* NOTE: \*\*At time of post-transplant relapse~PATIENT CHARACTERISTICS:~Age~* 14 and over (patients \< 14 years of age may be eligible if they are deemed to be of sufficient height and weight by the pediatric attending physician)~Performance status~* Karnofsky 60-100% (at time of post-transplant relapse)~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* No preexisting major nonhematopoietic organ toxicity ≥ grade 3 (at time of post-transplant relapse)~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Concurrent immunosuppressive steroid therapy for GVHD allowed provided both of the following are true:~  * Able to taper steroid dose to \< 0.5 mg/kg/day~ * No increase of \> 1 grade in acute GVHD OR progression of chronic GVHD within 14 days after dose change~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).